View in EDS HTML Full Text PDF Full Text

Epigenetic dysregulation of metabolic programs mediates liposarcoma cell plasticity.

Saved in:
Bibliographic Details
Title: Epigenetic dysregulation of metabolic programs mediates liposarcoma cell plasticity.
Authors: Pimenta EM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.; Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA.; Sarcoma Center, Dana-Farber Cancer Institute, Boston, MA 02115, USA.; David Liposarcoma Research Initiative, Dana-Farber Cancer Institute, Boston, MA 02115, USA., Garza AE; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.; Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA., Camp SY; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.; Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA., Park J; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.; Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA., Hoffman SE; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.; Harvard Division of Medical Sciences PhD Program in Biological and Biomedical Sciences, Boston, MA 02115, USA.; Harvard-MIT MD-PhD Program, Harvard Medical School, Boston, MA 02115, USA., Valderrábano L; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.; Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA., Fu J; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.; Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA.; Harvard Medical School, Boston, MA 02115, USA.; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA 02115, USA., Bi K; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.; Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA.; Center for Cancer Genomics, Dana-Farber Cancer Institute, Boston, MA 02115, USA., Carson MT; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.; Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA., Karam J; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.; Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA., Titchen BM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.; Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA.; Harvard Division of Medical Sciences PhD Program in Biological and Biomedical Sciences, Boston, MA 02115, USA., Medjahed S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA., Khandekar MJ; David Liposarcoma Research Initiative, Dana-Farber Cancer Institute, Boston, MA 02115, USA.; Harvard Medical School, Boston, MA 02115, USA.; Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA 02114, USA., Shannon E; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.; Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA., Kang YJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.; Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA.; Department of Surgery, Brigham and Women's Hospital, Boston, MA 02115, USA., Coy S; Harvard Medical School, Boston, MA 02115, USA.; Department of Pathology, Brigham and Women's Hospital, Boston, MA 02115, USA.; Ludwig Center at Harvard, Boston, MA 02115, USA.; Laboratory of Systems Pharmacology, Harvard Medical School, Boston, MA 02115, USA., Lin JR; Laboratory of Systems Pharmacology, Harvard Medical School, Boston, MA 02115, USA., Nag A; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.; Center for Cancer Genomics, Dana-Farber Cancer Institute, Boston, MA 02115, USA., Thorner AR; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.; Center for Cancer Genomics, Dana-Farber Cancer Institute, Boston, MA 02115, USA., Gibson WJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.; Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA., Santagata S; Department of Pathology, Brigham and Women's Hospital, Boston, MA 02115, USA.; Laboratory of Systems Pharmacology, Harvard Medical School, Boston, MA 02115, USA., Raut CP; Sarcoma Center, Dana-Farber Cancer Institute, Boston, MA 02115, USA.; Harvard Medical School, Boston, MA 02115, USA.; Department of Surgery, Brigham and Women's Hospital, Boston, MA 02115, USA., Hornick JL; Sarcoma Center, Dana-Farber Cancer Institute, Boston, MA 02115, USA.; Department of Pathology, Brigham and Women's Hospital, Boston, MA 02115, USA., Merriam P; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.; Sarcoma Center, Dana-Farber Cancer Institute, Boston, MA 02115, USA., Solimini NL; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.; Sarcoma Center, Dana-Farber Cancer Institute, Boston, MA 02115, USA.; David Liposarcoma Research Initiative, Dana-Farber Cancer Institute, Boston, MA 02115, USA.; Ludwig Center at Harvard, Boston, MA 02115, USA., George S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.; Sarcoma Center, Dana-Farber Cancer Institute, Boston, MA 02115, USA.; Harvard Medical School, Boston, MA 02115, USA., Demetri GD; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.; Sarcoma Center, Dana-Farber Cancer Institute, Boston, MA 02115, USA.; David Liposarcoma Research Initiative, Dana-Farber Cancer Institute, Boston, MA 02115, USA.; Harvard Medical School, Boston, MA 02115, USA.; Ludwig Center at Harvard, Boston, MA 02115, USA., Van Allen EM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.; Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA.; David Liposarcoma Research Initiative, Dana-Farber Cancer Institute, Boston, MA 02115, USA.; Parker Institute for Cancer Immunotherapy, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
Source: Science translational medicine [Sci Transl Med] 2026 Jan 21; Vol. 18 (833), pp. eadw4689. Date of Electronic Publication: 2026 Jan 21.
Publication Type: Journal Article
Journal Info: Publisher: American Association for the Advancement of Science Country of Publication: United States NLM ID: 101505086 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1946-6242 (Electronic) Linking ISSN: 19466234 NLM ISO Abbreviation: Sci Transl Med Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
Description
ISSN:1946-6242
DOI:10.1126/scitranslmed.adw4689